Alzheimer’s is the white whale of the pharmaceutical world. This week a new Captain Ahab came on the scene with some new tools for hunting down an old target.
Seattle-based AltPep Corporation raised $23.15 million in a Series A financing round to take their breakthrough amyloid targeting platform to development. Based on technology developed at a University of Washington (UW) lab, the biotech has three targets: early diagnostic for Alzheimer’s Disease (AD), anti-biofilm therapies and coatings and disease-modifying therapeutics for AD.